Overview

• Cardiac surgery firm's Q4 revenue slightly missed analyst expectations

• Adjusted net income for Q4 beat analyst estimates

• Company saw significant growth in stent grafts and On-X product lines

Outlook

• Artivion expects 2026 revenue between $486 mln and $504 mln

• Company anticipates 2026 adjusted EBITDA growth of 18% to 22%

• Artivion aims for sustained double-digit revenue growth long-term

Result Drivers

• PRODUCT LINE GROWTH - Revenue growth driven by 44% increase in stent grafts and 25% increase in On-X product lines, per CEO Pat Mackin

• CLINICAL DATA - Positive clinical data from NEXUS TRIOMPHE IDE trial showed 94% patient survival and low morbidity, presented at STS Annual Meeting

• PMA APPLICATION - Filed final module of PMA application for AMDS Hybrid Prothesis, indicating progress in product development

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Artivion Inc is $53.00, about 32.2% above its February 11 closing price of $40.10

• The stock recently traded at 89 times the next 12-month earnings vs. a P/E of 130 three months ago

Press Release: ID:nPnM2Kzpa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)